Cardiol Therapeutics On Track To Provide New Standard Of Care For Cardiovascular Diseases ($CRDL)
While Cardiol Therapeutics stock may have given back some of its gains to profit-taking, investors holding since the new year have little to complain about. After all, since the turn to 2023, CRDL...
Source: marketscreener.com